- Oops!Something went wrong.Please try again later.
Looking at Q4, Mednax (NYSE:MD) earned $32.30 million, a 57.9% increase from the preceding quarter. Mednax's sales decreased to $416.63 million, a 9.55% change since Q3. In Q3, Mednax earned $20.46 million, whereas sales reached $460.63 million.
What Is ROCE?
Changes in earnings and sales indicate shifts in Mednax's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Mednax posted an ROCE of 0.04%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Mednax is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.
For Mednax, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.
Q4 Earnings Recap
Mednax reported Q4 earnings per share at $0.25/share, which did not meet analyst predictions of $0.36/share.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.